Targeted O-glycoproteomics explored increased sialylation and identified MUC16 as a poor prognosis biomarker in advanced-stage bladder tumours.
Cotton S, Azevedo R, Gaiteiro C, Ferreira D, Lima L, Peixoto A, Fernandes E, Neves M, Neves D, Amaro T, Cruz R, Tavares A, Rangel M, Silva AMN, Santos LL, Ferreira JA.
Cotton S, et al. Among authors: santos ll.
Mol Oncol. 2017 Aug;11(8):895-912. doi: 10.1002/1878-0261.12035. Epub 2017 Mar 2.
Mol Oncol. 2017.
PMID: 28156048
Free PMC article.